iuvo BioScience, ann industry leading CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to biopharmaceutical and medical device customers, has hired Sanjeev Ganatra, MBA, as their Chief Commercial Officer. This hire demonstrates iuvo's continued commitment to client service, differentiated expertise, and investment in the business to support the company's growth trajectory. Ganatra is a well-established operational and business executive who brings years of experience in sales, marketing, business and corporate development both in pharma service companies as well as commercial organizations.
ROCHESTER, N.Y., April 4, 2023 /PRNewswire-PRWeb/ -- iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to biopharmaceutical and medical device customers, today announced it has hired Sanjeev Ganatra, MBA, as their Chief Commercial Officer. This hire demonstrates iuvo's continued commitment to client service, differentiated expertise, and investment in the business to support the company's growth trajectory.
Ganatra is a well-established operational and business executive who brings years of experience in sales, marketing, business and corporate development both in pharma service companies as well as commercial organizations. Ganatra spent his early years in pharmaceutical and medical device development organizations before moving into the pharma services business. He spent three years with a global ophthalmic CRO, and most recently was the SVP of Sales and Marketing and Global Head of Ophthalmology at CBCC Global Research.
Ganatra is excited about joining the iuvo team, stating, "The journey that has led iuvo to its current level of success is attributed to the combination of a great team, excellent service, and collaborative clients. My goal is to help further build on this platform, creating new opportunities for our team to demonstrate their talent and for our clients to have a comprehensive partner for their development needs."
Daniel Spasic, Board Chair of iuvo BioScience, offered his welcome as well, "We've all been impressed by Sanjeev's accomplishments in sales and customer service, as well as his deep understanding of operational aspects in executing ophthalmology trials. He will be welcomed into a fast-paced ophthalmology business that span services from pre-clinical, scientific consulting and clinical development, where his contribution will be essential to our continued growth."
Ben Burton, CEO of iuvo BioScience, provided these final comments, "As we enter the next phase of our company, Sanjeev will play an important role in our PROTM (Partner Research Organization) Model as we continue to serve clients across the globe. Sanjeev's demonstrated expertise in client service is a perfect cultural fit for our team, and his business acumen and performance track record will create value immediately for iuvo BioScience. We are excited to have Sanjeev on-board."
About iuvo BioScience
Headquartered in Rochester, NY, iuvo BioScience is a highly specialized provider of preclinical, clinical, and consulting services to biotech and medical device customers. The company's facility features laboratories for analytical chemistry, microbiology, pharmacology, and toxicology, as well as an on-site AAALAC-accredited vivarium to support preclinical testing. Through the company's Oculos Clinical Research subsidiary, iuvo provides a suite of clinical trial services including clinical trial design, regulatory, biometrics, pharmacovigilance, project and site management. Under the Lumino Advisors brand, the company also has an end-to-end scientific consulting offering spanning from regulatory strategy, dossier development, preclinical and CMC consulting and strategic planning through trial execution and regulatory submission. Additional information about iuvo is available at http://www.iuvobioscience.com
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm with more than $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit http://www.ampersandcapital.com or follow us on LinkedIN at https://www.linkedin.com/company/ampersand-capital-partners/.
Media Contact
Ben Burton, iuvo BioScience, 1 585-260-1672, [email protected]
SOURCE iuvo BioScience
Share this article